^
    Apply
    A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (NCT06115135)
    Phase 2
    Oncotherapeutics
    Not yet recruiting
    Last update posted :
    01/24/2024
    Initiation :
    03/01/2024
    Primary completion :
    03/31/2026
    Completion :
    12/31/2026
    BCL2 • TNFA
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection
    S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis (NCT03499808)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    01/04/2024
    Initiation :
    06/06/2018
    Primary completion :
    12/31/2023
    Completion :
    07/31/2025
    NPPB
    |
    Chr t(11;14) • Chr t(4;14) • Chr t(14;16)
    |
    Sarclisa (isatuximab-irfc)
    A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (TTI-622-01) (NCT03530683)
    Phase 1
    Pfizer
    Active, not recruiting
    Last update posted :
    12/22/2023
    Initiation :
    06/07/2018
    Primary completion :
    09/11/2024
    Completion :
    09/11/2024
    TP53
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) (ISABEL) (NCT04965155)
    Phase 2
    EMN Research Italy
    Active, not recruiting
    Last update posted :
    12/19/2023
    Initiation :
    03/21/2021
    Primary completion :
    11/28/2023
    Completion :
    03/31/2027
    CD34
    |
    carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • melphalan
    Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies (NCT01084252)
    Phase 1/2
    Sanofi
    Completed
    Last update posted :
    10/06/2023
    Initiation :
    06/10/2010
    Primary completion :
    12/21/2018
    Completion :
    07/13/2023
    IFNG • IL6 • TNFA • CRP
    |
    dexamethasone • Sarclisa (isatuximab-irfc)
    Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy (ICING) (NCT04763616)
    Phase 2
    Won Seog Kim
    Recruiting
    Last update posted :
    09/24/2021
    Initiation :
    06/25/2021
    Primary completion :
    04/30/2023
    Completion :
    04/30/2026
    PD-L1
    |
    Libtayo (cemiplimab-rwlc) • Sarclisa (isatuximab-irfc)